Vir/GSK Move Lead Coronavirus Antibody Into Phase III
Safety In 20 Phase II Patients Enabled Testing In 1,300 People
Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.
You may also be interested in...
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.
The FDA granted emergency authorization for Moderna's mRNA-1273 following a 17 December advisory committee vote in its favor. There have also been more supply deals and approvals in Asia.
Having been under GSK's umbrella since 1985, SR One is striking out on its own, having closed the largest first-time VC fund this year.